Pertussis toxin

Pertussis toxin (PT), secreted protein exotoxin and virulence factor by Bordetella pertussis, is the causative agent of whooping cough. It is transported across the bacterial outer membrane through a type IV secretion system encoded by the ptl genes, situated downstream from the ptx genes that encode the toxin. This complex multisubunit toxin with an AB5 configuration, serves as a crucial component of acellular pertussis vaccines. It can function protectively as a single-component toxoid vaccine. Moreover, it is widely used in mammalian cell signaling studies due to its inhibitory effect on G-protein-coupled receptor pathways. It inhibits neutrophil recruitment and airway influx, a common inflammatory response to bacterial infection.

Pertussis Toxin, Bordetella pertussis has been used as a Gi protein inhibitor to study its ability to reduce the depolarizing responses of hypothalamic pro-opiomelanocortin (POMC) neurons. It has also been used in pertussis toxin experiments to block Gαi for an in vivo inner ear and an in vitro outer hair cell (HC) study.

Primary Target
Guanine nucleotide-binding regulatory proteins Gi, Go, and Gt

Product does not compete with ATP.

Lyophilized from 50 mM NaCl, 10 mM sodium phosphate buffer, pH 7.0.

Following reconstitution, refrigerate (4°C). For long-term storage in solution, reconstitute with a high ionic strength buffer, such as 100 mM sodium phosphate, 500 mM sodium chloride, pH 7.0. Stock solutions are stable for at least 6 months for use in CHO cell assays and for 1-2 months for use in non-cellular systems.

Reconstitute with 500 µl H₂O. Obtain a uniform suspension before each use by scraping the walls of the tube and gently pipetting the solution to mix.

Five distinct bands by SDS-PAGE

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Joshi, S.A., et al. 1998. FEBS Lett. 441, 67.
Fryer, M.W. 1992. Neurosci. Lett.146, 84.
Gierschik, P. 1992. Curr. Topics Microbiol. Immunol.175, 69.
Harada, J., et al. 1992. Eur. J. Pharmacol.227, 301.
Hausman, S.Z., and Burns, D.L. 1992. J. Biol. Chem.267, 13735.
Kaslow, H.R., and Burns, D.L., 1992. FASEB J.6, 2684.
Zhu, J., et al. 1992. J. Pharmacol. Exp. Therap.263, 1479.
Hewlett, E.L., et al. 1983. Infect. Immun.40, 1198.
Moss, J., et al. 1983. J. Biol. Chem.258, 11879.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Toxic (F)